EMA Authorised: Vimpat (lacosamide) — UCB Pharma SA

View source ↗

Summary

Authorised status for Vimpat (lacosamide) by EMA under UCB Pharma SA for epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Vimpat (lacosamide)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: UCB Pharma SA. Decision date: 23/07/2026